SDBN Blog, News

Life Science Events, Jobs, Directory, News

 

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
2026-04-01 13:07 UTC by SDBN

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME).

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


 

Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative.